Enavogliflozin, also known by the development code DWP16001, is a selective inhibitor of the sodium-glucose cotransporters SLC5A2 and SGLT2. It was developed by GC Pharma and Daewoong Pharmaceutical to treat diabetes and obesity. According to its encyclopedia article it has been approved for clinical use in South Korea and Ecuador, and approval applications have been made in Brazil, Mexico, Peru and Colombia. A meta-analysis of four trials over six months of clinical use found it well tolerated and effective for managing type 2 diabetes. This entry records what the source lead states and is not medical advice.
Facts
Partially Attested
Approved UseType 2 diabetes mellitus, studied as an add-on to metformin 4 The source is a phase 3 trial report, not a regulatory label. It documents the studied use, type 2 diabetes as add-on to metformin, and does not itself state the labeled indication. Classification
Approval Status ATC ClassA: Alimentary Tract and Metabolism 2 Mechanism of ActionSelective inhibitor of the sodium-glucose cotransporter-2 (SGLT2) 4 Connections
Long-Form Articles
Treats
Source Enavogliflozin (Wikipedia)
Sources
1. Enavogliflozin (Wikipedia)
Lead paragraph
Enavogliflozin has been approved for clinical use in South Korea, and Ecuador
Treats: Diabetes Mellitus, Lead paragraph [treats]
developed to treat diabetes and obesity
View the Source2. WHO Collaborating Centre for Drug Statistics Methodology, ATC/DDD Index: the WHO ATC/DDD Index entries named Enavogliflozin
WHO Collaborating Centre for Drug Statistics Methodology, ATC/DDD IndexATC/DDD Index entry; ATC class derived from cited code A10BK09 (main group A)Quote, ATC/DDD Index entry; ATC class derived from cited code A10BK09 (main group A)
A10BK09 enavogliflozin
3. Navigating the Future of Diabetes Treatment with New Drugs: Focusing on the Possibilities and Prospects of Enavogliflozin (Diabetes & Metabolism Journal, 2023)
Opening sentenceQuote, Opening sentence
Enavogliflozin, a novel SGLT2 inhibitor, has garnered much attention
4. Efficacy and Safety of Enavogliflozin versus Dapagliflozin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus (Diabetes & Metabolism Journal, 2023)
Introduction
Enavogliflozin is a novel SGLT-2 selective inhibitor that is currently under clinical development stage.
Abstract, Background
This study evaluated the efficacy and safety of enavogliflozin as an add-on to metformin in Korean patients with type 2 diabetes mellitus (T2DM) against dapagliflozin.
View the SourceReader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.